1
|
Zhuo X, Jasiukenaite I, Löbmann K. β-Lactoglobulin-based amorphous solid dispersions: A graphical review on the state-of-the-art. Eur J Pharm Biopharm 2024; 202:114396. [PMID: 38971201 DOI: 10.1016/j.ejpb.2024.114396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2024] [Revised: 06/27/2024] [Accepted: 07/03/2024] [Indexed: 07/08/2024]
Abstract
Proteins have recently caught attention as potential excipients for amorphous solid dispersions (ASDs) to improve oral bioavailability of poorly water-soluble drugs. Notably, the studies have highlighted whey protein isolates, particularly β-lactoglobulin (BLG), as promising candidates in amorphous stabilization, dissolution and solubility enhancement, achieving drug loadings of 50 wt% and higher. Consequently, investigations into the mechanisms underlying the solid-state stabilization of amorphous drugs and the enhancement of drug solubility in solution have been conducted. This graphical review provides a comprehensive overview of recent findings concerning BLG-based ASDs. Firstly, the dissolution performance of BLG-based ASDs is compared to more traditional polymer-based ASDs. Secondly, the drug loading onto BLG and the resulting amorphous stabilization mechanisms is summarized. Thirdly, interactions between BLG and drug molecules in solution are described as the mechanisms governing the improvement of drug solubility. Lastly, we outline the impact of the spray drying process on the secondary structure of BLG, and the resulting differences in amorphous stabilization and drug dissolution performance between α-helix-rich and β-sheet-rich BLG-based ASDs.
Collapse
Affiliation(s)
- Xuezhi Zhuo
- Zerion Pharma A/S, Fruebjergvej 3, 2100 Copenhagen, Denmark
| | | | | |
Collapse
|
2
|
Xu X, Grohganz H, Rades T. Anti-plasticizing effect of water on prilocaine and lidocaine - the role of the hydrogen bonding pattern. Phys Chem Chem Phys 2024; 26:14149-14159. [PMID: 38712380 DOI: 10.1039/d4cp00995a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2024]
Abstract
It is generally accepted that water, as an effective plasticizer, decreases the glass transition temperatures (Tgs) of amorphous drugs, potentially resulting in physical instabilities. However, recent studies suggest that water can also increase the Tgs of the amorphous forms of the drugs prilocaine (PRL) and lidocaine (LID), thus acting as an anti-plasticizer. To further understand the nature of the anti-plasticizing effect of water, interactions with different solvents and the resulting structural features of PRL and LID were investigated by Fourier transform infrared spectroscopy (FTIR) and quantum chemical simulations. Heavy water (deuterium oxides) was chosen as a solvent, as the deuterium and hydrogen atoms are electronically identical. It was found that substituting hydrogen with deuterium showed a minimal impact on the anti-plasticization of water on PRL. Ethanol and ethylene glycol were chosen as solvents to compare the hydrogen bonding patterns occurring between the hydroxyl groups of the solvents and PRL and LID. Comparison of the various Tgs showed a weaker anti-plasticizing potential of these two solvents on PRL and LID. The frequency shifts of the amide CO groups of PRL and LID due to the interactions with water, heavy water, ethanol, and ethylene glycol as observed in the FTIR spectra showed a correlation with the binding energies calculated by quantum chemical simulations. Overall, this study showed that the combination of weak hydrogen bonding and strong electrostatic contributions in hydrated PRL and LID could play an important role in inducing the anti-plasticizing effect of water on those drugs.
Collapse
Affiliation(s)
- Xiaoyue Xu
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Thomas Rades
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| |
Collapse
|
3
|
Aljabbari A, Kihara S, Rades T, Boyd BJ. The biomolecular gastrointestinal corona in oral drug delivery. J Control Release 2023; 363:536-549. [PMID: 37776905 DOI: 10.1016/j.jconrel.2023.09.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 09/24/2023] [Accepted: 09/27/2023] [Indexed: 10/02/2023]
Abstract
The formation of a biomolecular corona on exogenous particles in plasma is well studied and is known to dictate the biodistribution and cellular interactions of nanomedicine formulations. In contrast, while the oral route is the most favorable administration method for pharmaceuticals, little is known about the formation and composition of the corona formed by biomolecules on particles within the gastrointestinal tract. This work reviews the current literature understanding of (1) the formation of drug particles after oral administration, (2) the formation of a biomolecular corona within the gastrointestinal tract ("the gastrointestinal corona"), and (3) the possible implications of the formation of a gastrointestinal corona on the interactions of drug particles with their biological environment. In doing so, this work aims to establish the significance of the formation of a gastrointestinal corona in oral drug delivery to ultimately arrive at new avenues to control the behavior of orally administered pharmaceuticals.
Collapse
Affiliation(s)
- Anas Aljabbari
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen Ø 2100, Denmark
| | - Shinji Kihara
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen Ø 2100, Denmark
| | - Thomas Rades
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen Ø 2100, Denmark
| | - Ben J Boyd
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen Ø 2100, Denmark; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
| |
Collapse
|
4
|
Engelsing F, Buchart L, Grohganz H. Design of experiments approach on the compaction properties of co-amorphous tablets. Pharm Dev Technol 2023; 28:907-914. [PMID: 37869788 DOI: 10.1080/10837450.2023.2274390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Accepted: 10/19/2023] [Indexed: 10/24/2023]
Abstract
Co-amorphous systems are an evolving strategy to stabilize the amorphous form of a drug molecule with the aim of overcoming its poor water-solubility. With research focussing on the molecular level of co-amorphous systems, little is known about their downstream processing. In this study, tablets of co-amorphous carvedilol and aspartic acid (CAR-ASP) with calcium hydrogen phosphate and croscarmellose sodium as excipients were produced using a compaction simulator. The amorphous form of spray dried CAR-ASP and the subsequently produced tablets was confirmed with XRPD. Over the storage time of 12 weeks, no recrystallization of the amorphous material was observed. A central composite face-centred design with three factors was set up to investigate the interplay of formulation and processing variables with the tablet characteristics elastic work, tensile strength and disintegration time. As a result, increasing the amount of co-amorphous material led to a decrease in elastic work and an increased tensile strength. These effects were beneficial for tablet properties, namely harder tablets and reduced elasticity. Disintegration time was prolonged by amounts of up to 25-30% co-amorphous material, while larger amounts induced faster tablet disintegration. While showing the feasibility of compacting co-amorphous material with calcium hydrogen phosphate, this study also gives insight into how tablet characteristics are affected by co-amorphous material and relevant process parameters.
Collapse
Affiliation(s)
- Florian Engelsing
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
| | - Laura Buchart
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
5
|
Schütz D, Timmerhaus A, Grohganz H. Wet granulation of co-amorphous indomethacin systems. Int J Pharm 2023; 644:123318. [PMID: 37586574 DOI: 10.1016/j.ijpharm.2023.123318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Revised: 08/11/2023] [Accepted: 08/13/2023] [Indexed: 08/18/2023]
Abstract
The feasibility of co-amorphous systems to be wet granulated together with microcrystalline cellulose (MCC) was investigated. Solid state and molecular interactions were analysed for various co-amorphous drug-amino acid formulations of indomethacin with tryptophan and arginine, respectively, via XRPD, DSC and FTIR. The co-amorphous binary systems were produced by ball-milling for 90 min at different molar ratios followed by wet granulation with MCC and water in a miniaturised scale. Tryptophan containing systems showed crystalline reflections in their XRPD diffractograms and endothermal events in their DSC analyses, and were therefore excluded from upscaling attempts. The systems containing arginine were found to be remain amorphous for at least ten months and were upscaled for production in a high-shear blender under application of two different parameter settings. Under the harsher instrument settings, a composition with a low MCC ratio experienced recrystallisation during wet granulation, while all other compositions could be successfully processed via wet granulation and stayed stable for a storage period of at least twelve weeks, indicating that wet granulation of co-amorphous systems can be feasible.
Collapse
Affiliation(s)
- David Schütz
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
| | - Annika Timmerhaus
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
| |
Collapse
|
6
|
Nagy E, Kopniczky J, Smausz T, Náfrádi M, Alapi T, Bohus J, Pajer V, Szabó-Révész P, Ambrus R, Hopp B. A comparative study of femtosecond pulsed laser ablation of meloxicam in distilled water and in air. Sci Rep 2023; 13:10242. [PMID: 37353524 DOI: 10.1038/s41598-023-36922-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Accepted: 06/12/2023] [Indexed: 06/25/2023] Open
Abstract
The increasing prevalence of water insoluble or poorly soluble drugs calls for the development of new formulation methods. Common approaches include the reduction of particle size and degree of crystallinity. Pulsed laser ablation is a clean technique for producing sub-micrometre sized drug particles and has the potential to induce amorphization. We studied the effect of femtosecond pulsed laser ablation (ELI ALPS THz pump laser system: λc = 781 nm, τ = 135 fs) on meloxicam in distilled water and in air. The ablated particles were characterized chemically, morphologically and in terms of crystallinity. We demonstrated that femtosecond laser ablation can induce partial amorphization of the particles in addition to a reduction in particle size. In the case of femtosecond pulsed laser ablation in air, the formation of pure meloxicam spheres showed that this technique can produce amorphous meloxicam without the use of excipients, which is a unique result. We also aimed to describe the ablation processes in both investigated media.
Collapse
Affiliation(s)
- Eszter Nagy
- Department of Optics and Quantum Electronics, University of Szeged, Dóm tér 9, Szeged, 6720, Hungary
| | - Judit Kopniczky
- Department of Optics and Quantum Electronics, University of Szeged, Dóm tér 9, Szeged, 6720, Hungary
| | - Tamás Smausz
- Department of Optics and Quantum Electronics, University of Szeged, Dóm tér 9, Szeged, 6720, Hungary
| | - Máté Náfrádi
- Department of Inorganic and Analytical Chemistry, University of Szeged, Dóm tér 7, Szeged, 6720, Hungary
| | - Tünde Alapi
- Department of Inorganic and Analytical Chemistry, University of Szeged, Dóm tér 7, Szeged, 6720, Hungary
| | - János Bohus
- ELI ALPS, ELI-HU Non-Profit Ltd., Wolfgang Sandner utca 3, Szeged, 6728, Hungary
| | - Viktor Pajer
- ELI ALPS, ELI-HU Non-Profit Ltd., Wolfgang Sandner utca 3, Szeged, 6728, Hungary
| | - Piroska Szabó-Révész
- Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös utca 6, Szeged, 6720, Hungary
| | - Rita Ambrus
- Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös utca 6, Szeged, 6720, Hungary
| | - Béla Hopp
- Department of Optics and Quantum Electronics, University of Szeged, Dóm tér 9, Szeged, 6720, Hungary.
| |
Collapse
|
7
|
Hoffmann L, Breitkreutz J, Quodbach J. Investigation of the degradation and in-situ amorphization of the enantiomeric drug escitalopram oxalate during Fused Deposition Modeling (FDM) 3D printing. Eur J Pharm Sci 2023; 185:106423. [PMID: 36918059 DOI: 10.1016/j.ejps.2023.106423] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 03/03/2023] [Accepted: 03/11/2023] [Indexed: 03/14/2023]
Abstract
Hot-melt extrusion (HME) and subsequent FDM 3D printing offer great potential opportunities in the formulation development and production of customized oral dosage forms with poorly soluble drugs. However, thermal stress within these processes can be challenging for thermo-sensitive drugs. In this work, three different formulations were prepared to investigate the degradation and the solid state of the thermo-sensitive and poorly soluble drug escitalopram oxalate (ESC-OX) during the two heat-intensive processes HME and FDM 3D printing. For this purpose, hydroxypropyl methyl cellulose (HPMC) and basic butylated methacrylate copolymer (bPMMA) were chosen as polymers. DSC and XRD measurements revealed that ESC-OX is amorphous in the HPMC based formulations in both, extrudates and 3D printed tablets. In contrast, in-situ amorphization of the drug from crystalline state in bPMMA filaments was observed during FDM 3D printing. With regard to the content, it was found that degradation of ESC-OX in extrudates with bPMMA could be avoided and in 3D printed tablets almost fully reduced. Furthermore, a possible conversion into the R-enantiomer in the formulation with bPMMA could be excluded using a chiral column. Compared to the commercial product Cipralex®, drug release from extrudates and tablets with bPMMA was slower but still qualified as immediate drug release.
Collapse
Affiliation(s)
- Lena Hoffmann
- Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, Universitätsstraße 1, 40225 Düsseldorf, Germany
| | - Jörg Breitkreutz
- Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, Universitätsstraße 1, 40225 Düsseldorf, Germany
| | - Julian Quodbach
- Department of Pharmaceutics, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands.
| |
Collapse
|
8
|
Sørensen CM, Rantanen J, Grohganz H. Compaction Behavior of Co-Amorphous Systems. Pharmaceutics 2023; 15:pharmaceutics15030858. [PMID: 36986718 PMCID: PMC10056350 DOI: 10.3390/pharmaceutics15030858] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 03/01/2023] [Accepted: 03/04/2023] [Indexed: 03/09/2023] Open
Abstract
Co-amorphous systems have been shown to be a promising strategy to address the poor water solubility of many drug candidates. However, little is known about the effect of downstream processing-induced stress on these systems. The aim of this study is to investigate the compaction properties of co-amorphous materials and their solid-state stability upon compaction. Model systems of co-amorphous materials consisting of carvedilol and the two co-formers aspartic acid and tryptophan were produced via spray drying. The solid state of matter was characterized using XRPD, DSC, and SEM. Co-amorphous tablets were produced with a compaction simulator, using varying amounts of MCC in the range of 24 to 95.5% (w/w) as a filler, and showed high compressibility. Higher contents of co-amorphous material led to an increase in the disintegration time; however, the tensile strength remained rather constant at around 3.8 MPa. No indication of recrystallization of the co-amorphous systems was observed. This study found that co-amorphous systems are able to deform plastically under pressure and form mechanically stable tablets.
Collapse
|
9
|
Dimiou S, McCabe J, Booth R, Booth J, Nidadavole K, Svensson O, Sparén A, Lindfors L, Paraskevopoulou V, Mead H, Coates L, Workman D, Martin D, Treacher K, Puri S, Taylor LS, Yang B. Selecting Counterions to Improve Ionized Hydrophilic Drug Encapsulation in Polymeric Nanoparticles. Mol Pharm 2023; 20:1138-1155. [PMID: 36653946 DOI: 10.1021/acs.molpharmaceut.2c00855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Hydrophobic ion pairing (HIP) can successfully increase the drug loading and control the release kinetics of ionizable hydrophilic drugs, addressing challenges that prevent these molecules from reaching the clinic. Nevertheless, polymeric nanoparticle (PNP) formulation development requires trial-and-error experimentation to meet the target product profile, which is laborious and costly. Herein, we design a preformulation framework (solid-state screening, computational approach, and solubility in PNP-forming emulsion) to understand counterion-drug-polymer interactions and accelerate the PNP formulation development for HIP systems. The HIP interactions between a small hydrophilic molecule, AZD2811, and counterions with different molecular structures were investigated. Cyclic counterions formed amorphous ion pairs with AZD2811; the 0.7 pamoic acid/1.0 AZD2811 complex had the highest glass transition temperature (Tg; 162 °C) and the greatest drug loading (22%) and remained as phase-separated amorphous nanosized domains inside the polymer matrix. Palmitic acid (linear counterion) showed negligible interactions with AZD2811 (crystalline-free drug/counterion forms), leading to a significantly lower drug loading despite having similar log P and pKa with pamoic acid. Computational calculations illustrated that cyclic counterions interact more strongly with AZD2811 than linear counterions through dispersive interactions (offset π-π interactions). Solubility data indicated that the pamoic acid/AZD2811 complex has a lower organic phase solubility than AZD2811-free base; hence, it may be expected to precipitate more rapidly in the nanodroplets, thus increasing drug loading. Our work provides a generalizable preformulation framework, complementing traditional performance-indicating parameters, to identify optimal counterions rapidly and accelerate the development of hydrophilic drug PNP formulations while achieving high drug loading without laborious trial-and-error experimentation.
Collapse
Affiliation(s)
- Savvas Dimiou
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, CambridgeCB21 6GH, U.K.,UCL School of Pharmacy, 29-39 Brunswick Square, LondonWC1N 1AX, U.K
| | - James McCabe
- Early Product Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, MacclesfieldSK10 2NA, U.K
| | - Rebecca Booth
- New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, MacclesfieldSK10 2NA, U.K
| | - Jonathan Booth
- New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, MacclesfieldSK10 2NA, U.K
| | - Kalyan Nidadavole
- Early Product Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, MacclesfieldSK10 2NA, U.K
| | - Olof Svensson
- Pharmaceutical Technology & Development, Operations, AstraZeneca, GothenburgSE-43183, Sweden
| | - Anders Sparén
- Pharmaceutical Technology & Development, Operations, AstraZeneca, GothenburgSE-43183, Sweden
| | - Lennart Lindfors
- Advanced Drug Delivery, Pharmaceutical Science, R&D AstraZeneca, GothenburgSE-43183, Sweden
| | - Vasiliki Paraskevopoulou
- New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, MacclesfieldSK10 2NA, U.K
| | - Heather Mead
- New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, MacclesfieldSK10 2NA, U.K
| | - Lydia Coates
- New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, MacclesfieldSK10 2NA, U.K
| | - David Workman
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, CambridgeCB21 6GH, U.K
| | - Dave Martin
- New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, MacclesfieldSK10 2NA, U.K
| | - Kevin Treacher
- New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, MacclesfieldSK10 2NA, U.K
| | - Sanyogitta Puri
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, CambridgeCB21 6GH, U.K
| | - Lynne S Taylor
- Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana47907, United States
| | - Bin Yang
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, CambridgeCB21 6GH, U.K
| |
Collapse
|
10
|
Kaptan Y, Güvenilir Y. Polycaprolactone/epoxide-functionalized silica composite microparticles for long-term controlled release of trans-chalcone. JOURNAL OF POLYMER ENGINEERING 2022. [DOI: 10.1515/polyeng-2021-0343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Abstract
In this study, controlled release of trans-chalcone was achieved by using a polycaprolactone-based hybrid system as the drug carrier material. Encapsulation efficiency was obtained in the range of 70–75% for various formulations and in vitro release studies, conducted at 37 °C and pH 7.4, revealed slow profile reaching 60% cumulative release. As interpreted from kinetic modelling, drug release was controlled mainly by Fickian diffusion; polymer erosion did not contribute to the TC release. Difference in drug loading efficiencies of the hybrid and neat PCL microparticles was observed such that PCL microparticles had lower loading efficiency than the hybrid microparticles whereas the release profiles were similar. pH of the release medium had affected release profiles; acidic medium enhanced drug release. Characterization of the microparticles were realized by FT-IR, TGA, DSC, SEM and WCA which revealed key properties such as molecular dispersion state and hydrophilicity. With the results obtained, we concluded that our hybrid system has a significant potential for long term release of trans-chalcone.
Collapse
Affiliation(s)
- Yasemin Kaptan
- Department of Chemical Engineering , Istanbul Technical University , İstanbul 34469 , Turkey
| | - Yüksel Güvenilir
- Department of Chemical Engineering , Istanbul Technical University , İstanbul 34469 , Turkey
| |
Collapse
|
11
|
Development of a multiparticulate drug delivery system for in situ amorphisation. Eur J Pharm Biopharm 2022; 180:170-180. [PMID: 36191869 DOI: 10.1016/j.ejpb.2022.09.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 09/20/2022] [Accepted: 09/24/2022] [Indexed: 11/23/2022]
Abstract
In the current study, the concept of multiparticulate drug delivery systems (MDDS) was applied to tablets intended for the amorphisation of supersaturated granular ASDs in situ, i.e. amorphisation by microwave irradiation within the final dosage form. The MDDS concept was hypothesised to ensure geometric and structural stability of the dosage form and to improve the in vitro disintegration and dissolution characteristics. Granules were prepared in two sizes (small and large) containing the crystalline drug celecoxib (CCX) and polyvinylpyrrolidone/vinyl acetate copolymer (PVP/VA) at a 50 % w/w drug load as well as sodium dihydrogen phosphate monohydrate as the microwave absorbing excipient. The granules were subsequently embedded in an extra-granular tablet phase composed of either the filler microcrystalline cellulose (MCC) or mannitol (MAN), as well as the disintegrant crospovidone and the lubricant magnesium stearate. The tensile strength and disintegration time were investigated prior to and after 10 min of microwave irradiation (800 and 1000 W) and the formed ASDs were characterised by X-ray powder diffraction and modulated differential scanning calorimetry. Additionally, the internal structure was elucidated by X-ray micro-Computed Tomography (XµCT) and, finally, the dissolution performance of selected tablets was investigated. The MDDS tablets displayed no geometrical changes after microwave irradiation, however, the tensile strength and disintegration time increased. Complete amorphisation of CCX was achieved only for the MCC-based tablets at a power input of 1000 W, while MAN-based tablets displayed partial amorphisation independent of power input. The complete amorphisation of CCX was associated with the fusion of individual ASD granules within the tablets, which impacted the subsequent disintegration and dissolution performance. For these tablets, supersaturation was only observed after 60 min. On the other hand, the partially amorphised MDDS tablets displayed complete disintegration during the dissolution experiments, resulting in a fast onset of supersaturation within 5 min and an approx. 3.5-fold degree of supersaturation within the experimental timeframe (3 h). Overall, the MDDS concept was shown to potentially be a feasible dosage form for in situ amorphisation, however, there is still room for improvement to obtain a fully amorphous and disintegrating system.
Collapse
|
12
|
Holm TP, Knopp MM, Berthelsen R, Löbmann K. Supersaturated amorphous solid dispersions of celecoxib prepared by in situ microwave irradiation. Int J Pharm 2022; 626:122115. [PMID: 35985526 DOI: 10.1016/j.ijpharm.2022.122115] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 07/22/2022] [Accepted: 08/11/2022] [Indexed: 11/19/2022]
Abstract
This study investigated the ability of in situ amorphization using microwave irradiation in order to prepare highly supersaturated ASDs, i.e. ASDs with drug loads higher than the saturation solubility in the polymer at ambient temperature. For this purpose, compacts containing the crystalline drug celecoxib (CCX) and polyvinylpyrrolidone (PVP), polyvinylpyrrolidone-vinyl acetate copolymer (PVP/VA), or polyvinyl acetate (PVAc), were prepared at drug loads between 30-90 % w/w. Sodium dihydrogen phosphate (NaH2PO4) monohydrate was included in all compacts, as a source of water, to facilitate the dielectric heating of the compacts upon dehydration during microwave irradiation. After processing, the samples were analysed towards their solid state using X-ray powder diffraction (XRPD) and modulated differential scanning calorimetry (mDSC). Complete amorphisation of CCX was achieved across all the investigated polymers and with a maximal drug load of 90, 80, and 50 % w/w in PVP, PVP/VA, and PVAc, respectively. These drug loads corresponded to a 2.3-, 2.4-, and 10.0-fold supersaturation in the investigated polymers at ambient temperature. However, dissolution experiments with the in situ prepared ASDs in fasted state simulated intestinal fluid (FaSSIF), showed a lower initial drug release (0-2 hours) compared to equivalent physical mixtures of crystalline CCX and polymers or crystalline CCX alone. The lower drug release rate was explained by the fusion of individual drug and polymer particles during microwave irradiation and, subsequently, a lack of disintegration of the monolithic ASDs. Nevertheless, supersaturation of CCX in FaSSIF was achieved with the in situ amorphised ASDs with PVP and PVP/VA, albeit only after 3-24 h. Overall, the present study confirmed that it is feasible to prepare supersaturated ASDs in situ. However, in the current experimental setup, the monolithic nature of the resulting ASDs is considered a limiting factor in the practical applicability of this preparation method, due to limited disintegration and the associated negative effect on the drug release.
Collapse
Affiliation(s)
- Tobias Palle Holm
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | | | - Ragna Berthelsen
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | - Korbinian Löbmann
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
| |
Collapse
|
13
|
Abstract
Water is generally regarded as a universal plasticizer of amorphous drugs or amorphous drug-containing systems. A decrease in glass-transition temperature (Tg) is considered the general result of this plasticizing effect. A recent study exhibits that water can increase the Tg of amorphous prilocaine (PRL) and thus shows an anti-plasticizing effect. The structurally similar drug lidocaine (LID) might show similar interactions with water, and thus an anti-plasticizing effect of water is hypothesized to also occur in amorphous LID. However, the influence of water on the Tg of LID cannot be determined directly due to the very low stability of LID in the amorphous form. It is possible to predict the Tg of LID from a co-amorphous system of PRL-LID using the Gordon-Taylor equation. Interactions were observed between PRL and LID based on the deviations between the experimental Tgs and the Tgs calculated by the conventional use of the Gordon-Taylor equation. A modified use of the Gordon-Taylor equation was applied using the optimal co-amorphous system as a separate component and the excess drug as the other component. The predicted Tg of fully hydrated LID could thus be determined and was found to be increased by 0.9 ± 0.7 K compared with the Tg of water-free amorphous LID. It could be shown that water exhibited a small anti-plasticizing effect on LID.
Collapse
Affiliation(s)
- Xiaoyue Xu
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | - Thomas Rades
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| |
Collapse
|
14
|
Abstract
![]()
The effectiveness
of a partial least squares-discriminant analysis
coamorphous prediction model was tested using coamorphous screening
data for a promising coamorphous former, the dimer of N-vinyl(caprolactam) (bisVCap) with a range of active pharmaceutical
ingredients. The prediction model predicted 71% of the systems correctly.
An experimental coamorphous screen was performed with this coformer
with 13 different active pharmaceutical ingredients, and the results
were compared to the predictions from the model. A total of 85% of
the systems were correctly predicted. Stability assessments of three
coamorphous systems showed that the prediction model score did not
strongly correlate with the stability of the coamorphous material.
The model performed well with small-molecule coformers, such as bisVCap,
despite the difference in structure and properties compared to the
amino-acid-based model training set.
Collapse
Affiliation(s)
- Luke I Chambers
- Department of Chemistry, Durham University, Lower Mountjoy, Stockton Road, Durham DH1 3LE, U.K
| | - Osama M Musa
- Ashland LLC, 1005 Route 202/206, Bridgewater, New Jersey 08807, United States
| | - Jonathan W Steed
- Department of Chemistry, Durham University, Lower Mountjoy, Stockton Road, Durham DH1 3LE, U.K
| |
Collapse
|
15
|
Liu J, Hwu E, Bannow J, Grohganz H, Rades T. Impact of Molecular Surface Diffusion on the Physical Stability of Co-Amorphous Systems. Mol Pharm 2022; 19:1183-1190. [PMID: 35230110 DOI: 10.1021/acs.molpharmaceut.1c00973] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
In this study, surface diffusion of l-aspartic acid-carvedilol (ASP-CAR) co-amorphous systems at different ASP concentrations is measured and correlated with their physical stability. ASP-CAR films at ASP concentrations of 1-5% (w/w) were prepared by a newly developed method based on a vacuum compression molding process. Surface diffusion measurements were conducted on these systems based on the surface grating decay method using atomic force microscopy (AFM). The results demonstrate that a small amount of ASP (i.e., ≤ 5% w/w) in the co-amorphous systems could significantly slow down the grating decay process compared with that of pure amorphous CAR, indicating a reduced surface diffusion of CAR molecules. The decay time gradually increased in co-amorphous systems with increasing ASP concentration from 1 to 5% (w/w), with the longest observed decay time of around 800 h for the 5%ASP-CAR system, which was more than 200 times longer compared to the decay time of pure amorphous CAR (approximately 3 h). A good correlation between the decay constants of the pure amorphous CAR and co-amorphous films at ASP concentrations of 1-5% (w/w) and the physical stability of corresponding amorphous powder samples was found. Overall, this study provides a new method to prepare co-amorphous films for surface property measurements and reveals the impact of surface diffusion on the physical stability of co-amorphous systems.
Collapse
Affiliation(s)
- Jingwen Liu
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | - EnTe Hwu
- Department of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
| | - Jacob Bannow
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | - Thomas Rades
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| |
Collapse
|
16
|
Chen X, Ning L. Pharmaceutical cocrystals of nomegestrol acetate with superior dissolution. CrystEngComm 2022. [DOI: 10.1039/d2ce00870j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The improvement of solubility and dissolution properties are the focus of research on poorly water-soluble APIs.
Collapse
Affiliation(s)
- Xiaofeng Chen
- National Research Institute for Family Planning, 100081 China
| | - Lifeng Ning
- National Research Institute for Family Planning, 100081 China
| |
Collapse
|
17
|
Synthesis, Characterization, and Intrinsic Dissolution Studies of Drug-Drug Eutectic Solid Forms of Metformin Hydrochloride and Thiazide Diuretics. Pharmaceutics 2021; 13:pharmaceutics13111926. [PMID: 34834341 PMCID: PMC8620433 DOI: 10.3390/pharmaceutics13111926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Revised: 09/22/2021] [Accepted: 09/28/2021] [Indexed: 11/30/2022] Open
Abstract
The mechanochemical synthesis of drug–drug solid forms containing metformin hydrochloride (MET·HCl) and thiazide diuretics hydrochlorothiazide (HTZ) or chlorothiazide (CTZ) is reported. Characterization of these new systems indicates formation of binary eutectic conglomerates, i.e., drug–drug eutectic solids (DDESs). Further analysis by construction of binary diagrams (DSC screening) exhibited the characteristic V-shaped form indicating formation of DDESs in both cases. These new DDESs were further characterized by different techniques, including thermal analysis (DSC), solid state NMR spectroscopy (SSNMR), powder X-ray diffraction (PXRD) and scanning electron microscopy–energy dispersive X-ray spectroscopy analysis (SEM–EDS). In addition, intrinsic dissolution rate experiments and solubility assays were performed. In the case of MET·HCl-HTZ (χMET·HCl = 0.66), we observed a slight enhancement in the dissolution properties compared with pure HTZ (1.21-fold). The same analysis for the solid forms of MET·HCl-CTZ (χMET·HCl = 0.33 and 0.5) showed an enhancement in the dissolved amount of CTZ accompanied by a slight improvement in solubility. From these dissolution profiles and saturation solubility studies and by comparing the thermodynamic parameters (ΔHfus and ΔSfus) of the pure drugs with these new solid forms, it can be observed that there was a limited modification in these properties, not modifying the free energy of the solution (ΔG) and thus not allowing an improvement in the dissolution and solubility properties of these solid forms.
Collapse
|
18
|
Hempel NJ, Knopp MM, Zeitler JA, Berthelsen R, Löbmann K. Microwave-Induced in Situ Drug Amorphization Using a Mixture of Polyethylene Glycol and Polyvinylpyrrolidone. J Pharm Sci 2021; 110:3221-3229. [PMID: 34022194 DOI: 10.1016/j.xphs.2021.05.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 05/13/2021] [Accepted: 05/13/2021] [Indexed: 01/03/2023]
Abstract
The use of a mixture of polyethylene glycol (PEG) and polyvinylpyrrolidone (PVP) was investigated for microwave-induced in situ amorphization of celecoxib (CCX) inside compacts. Such amorphization requires the presence of a dipolar excipient in the formulation to ensure heating of the compact by absorption of the microwaves. Previously, the hygroscopic nature of PVP was exploited for this purpose. By exposing PVP-based compacts for set time intervals at defined relative humidity, controlled water sorption into the compacts was achieved. In the present study, PEG was proposed as the microwave absorbing excipient instead of water, to avoid the water sorption step. However, it was found that PEG alone melted upon exposure to microwave radiation and caused the compact to deform. Furthermore, CCX was found to recrystallize upon cooling in PEG-based formulations. Hence, a mixture of PEG and PVP was used, where the presence of PVP preserved the physical shape of the compact, and the physical state of the amorphous solid dispersion. To study the impact of the polymer mixture, different compact compositions of CCX, PEG and PVP were prepared. When exposing the compacts to microwave radiation, it was found that the PEG:PVP ratio was critical for in situ amorphization and that complete amorphization was only achieved above a certain temperature threshold.
Collapse
Affiliation(s)
| | | | - J Axel Zeitler
- Department of Chemical Engineering, University of Cambridge, Cambridge CB3 0AS, UK
| | - Ragna Berthelsen
- Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Korbinian Löbmann
- Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark.
| |
Collapse
|
19
|
Liu J, Rades T, Grohganz H. The influence of moisture on the storage stability of co-amorphous systems. Int J Pharm 2021; 605:120802. [PMID: 34144131 DOI: 10.1016/j.ijpharm.2021.120802] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 06/11/2021] [Accepted: 06/12/2021] [Indexed: 01/03/2023]
Abstract
Co-amorphization has been utilized to improve the physical stability of the respective neat amorphous drugs. However, physical stability of co-amorphous systems is mostly investigated under dry conditions, leaving the potential influence of moisture on storage stability unclear. In this study, carvedilol-L-aspartic acid (CAR-ASP) co-amorphous systems at CAR to ASP molar ratios from 3:1 to 1:3 were investigated under non-dry conditions at two temperatures, i.e., 25 °C 55 %RH and 40 °C 55 %RH. Under these conditions, the highest physical stability of CAR-ASP systems was observed at the 1:1 M ratio. This finding differed from the optimal molar ratio previously obtained under dry conditions (CAR-ASP 1:1.5). Molecular interactions between CAR and ASP were affected by moisture, and salt disproportionation occurred during storage. Morphological differences of systems at different molar ratios could be observed already after one week of storage. Furthermore, variable temperature X-ray powder diffraction measurements showed that excess CAR or excess ASP, existing in the binary systems, resulted in a faster recrystallization compared to equimolar system. Overall, this study emphasizes the influence of moisture on co-amorphous systems during storage, and provides options to determine the optimal ratio of co-amorphous systems in presence of moisture at comparatively short storage times.
Collapse
Affiliation(s)
- Jingwen Liu
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | - Thomas Rades
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| |
Collapse
|
20
|
Holm TP, Knopp MM, Löbmann K, Berthelsen R. Microwave induced in situ amorphisation facilitated by crystalline hydrates. Eur J Pharm Sci 2021; 163:105858. [PMID: 33887432 DOI: 10.1016/j.ejps.2021.105858] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 04/09/2021] [Accepted: 04/16/2021] [Indexed: 11/26/2022]
Abstract
Amorphisation within the final dosage form, i.e. in situ amorphisation, seeks to circumvent the potential stability issues associated with poorly soluble drugs in amorphous solid dispersions (ASDs). Microwave irradiation has previously been shown to enable in situ preparation of ASDs, when a high amount of microwave absorbing water was introduced into the final dosage form by conditioning at high relative humidity. In this study, an alternative to this conditioning step was investigated by introducing crystal water in form of sodium dihydrogen phosphate (NaH2PO4) di-, and monohydrate, in compacts prepared with 30 % w/w celecoxib (CCX) in polyvinylpyrrolidone K12 (PVP). As controls, compacts prepared with NaH2PO4 anhydrate and without NaH2PO4 were included in the study. The quantification of amorphous CCX after microwave irradiation showed an increase in CCX amorphicity for compacts containing NaH2PO4 di-, and monohydrate with increasing irradiation time. Complete amorphisation of CCX in compacts containing NaH2PO4 di-, and monohydrate was observed after 6 min, while no appreciable amorphisation was observed for the control compacts containing NaH2PO4 anhydrate and without NaH2PO4. Modulated differential scanning calorimetric analysis revealed that a homogenous ASD was formed after 12 min and 6 min for compacts containing NaH2PO4 di-, and monohydrate, respectively. Thermal gravimetric analysis indicated that NaH2PO4 monohydrate showed higher dehydration rates compared to the dihydrate, which in turn resulted in higher compact temperatures, and overall increased the rate of amorphisation and reduced the microwave irradiation time necessary to achieve a homogenous ASD. The present results confirmed the suitability of NaH2PO4 di- and monohydrate as alternative sources of water, the primary microwave absorbing material, for in situ microwave amorphisation. The use of crystalline hydrates as water reservoirs for in situ amorphisation circumvents the time-consuming and highly impractical conditioning step previously reported in order to achieve complete amorphisation. Additionally, it allows for easier and more accurate adjustment of the compacts water content, which directly affects the temperature reached during microwave irradiation, and thus, the rate of amorphisation.
Collapse
Affiliation(s)
- Tobias Palle Holm
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | | | - Korbinian Löbmann
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | - Ragna Berthelsen
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| |
Collapse
|
21
|
Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies. Pharmaceutics 2021; 13:pharmaceutics13030389. [PMID: 33804159 PMCID: PMC7999207 DOI: 10.3390/pharmaceutics13030389] [Citation(s) in RCA: 64] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 03/11/2021] [Accepted: 03/12/2021] [Indexed: 12/20/2022] Open
Abstract
Co-amorphous drug delivery systems (CAMS) are characterized by the combination of two or more (initially crystalline) low molecular weight components that form a homogeneous single-phase amorphous system. Over the past decades, CAMS have been widely investigated as a promising approach to address the challenge of low water solubility of many active pharmaceutical ingredients. Most of the studies on CAMS were performed on a case-by-case basis, and only a few systematic studies are available. A quantitative analysis of the literature on CAMS under certain aspects highlights not only which aspects have been of great interest, but also which future developments are necessary to expand this research field. This review provides a comprehensive updated overview on the current published work on CAMS using a quantitative approach, focusing on three critical quality attributes of CAMS, i.e., co-formability, physical stability, and dissolution performance. Specifically, co-formability, molar ratio of drug and co-former, preparation methods, physical stability, and in vitro and in vivo performance were covered. For each aspect, a quantitative assessment on the current status was performed, allowing both recent advances and remaining research gaps to be identified. Furthermore, novel research aspects such as the design of ternary CAMS are discussed.
Collapse
|
22
|
Kuentz M, Holm R, Kronseder C, Saal C, Griffin BT. Rational Selection of Bio-Enabling Oral Drug Formulations - A PEARRL Commentary. J Pharm Sci 2021; 110:1921-1930. [PMID: 33609523 DOI: 10.1016/j.xphs.2021.02.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Revised: 02/02/2021] [Accepted: 02/03/2021] [Indexed: 11/19/2022]
Abstract
New drug candidates often require bio-enabling formation technologies such as lipid-based formulations, solid dispersions, or nanosized drug formulations. Development of such more sophisticated delivery systems generally requires higher resource investment compared to a conventional oral dosage form, which might slow down clinical development. To achieve the biopharmaceutical objectives while enabling rapid cost effective development, it is imperative to identify a suitable formulation technique for a given drug candidate as early as possible. Hence many companies have developed internal decision trees based mostly on prior organizational experience, though they also contain some arbitrary elements. As part of the EU funded PEARRL project, a number of new decision trees are here proposed that reflect both the current scientific state of the art and a consensus among the industrial project partners. This commentary presents and discusses these, while also going beyond this classical expert approach with a pilot study using emerging machine learning, where the computer suggests formulation strategy based on the physicochemical and biopharmaceutical properties of a molecule. Current limitations are discussed and an outlook is provided for likely future developments in this emerging field of pharmaceutics.
Collapse
Affiliation(s)
- Martin Kuentz
- School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, CH 4132 Muttenz, Switzerland.
| | - René Holm
- Drug Product Development, Janssen Research and Development, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium; Department of Science and Environment, Roskilde University, 4000 Roskilde, Denmark
| | - Christian Kronseder
- School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, CH 4132 Muttenz, Switzerland
| | - Christoph Saal
- Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Brendan T Griffin
- School of Pharmacy, University College Cork, College Road, Cork, T12 YN60, Ireland
| |
Collapse
|
23
|
Abstract
Molecular dynamics (MD) simulations have become increasingly useful in the modern drug development process. In this review, we give a broad overview of the current application possibilities of MD in drug discovery and pharmaceutical development. Starting from the target validation step of the drug development process, we give several examples of how MD studies can give important insights into the dynamics and function of identified drug targets such as sirtuins, RAS proteins, or intrinsically disordered proteins. The role of MD in antibody design is also reviewed. In the lead discovery and lead optimization phases, MD facilitates the evaluation of the binding energetics and kinetics of the ligand-receptor interactions, therefore guiding the choice of the best candidate molecules for further development. The importance of considering the biological lipid bilayer environment in the MD simulations of membrane proteins is also discussed, using G-protein coupled receptors and ion channels as well as the drug-metabolizing cytochrome P450 enzymes as relevant examples. Lastly, we discuss the emerging role of MD simulations in facilitating the pharmaceutical formulation development of drugs and candidate drugs. Specifically, we look at how MD can be used in studying the crystalline and amorphous solids, the stability of amorphous drug or drug-polymer formulations, and drug solubility. Moreover, since nanoparticle drug formulations are of great interest in the field of drug delivery research, different applications of nano-particle simulations are also briefly summarized using multiple recent studies as examples. In the future, the role of MD simulations in facilitating the drug development process is likely to grow substantially with the increasing computer power and advancements in the development of force fields and enhanced MD methodologies.
Collapse
|
24
|
Tomar D, Singh PK, Hoque S, Modani S, Sriram A, Kumar R, Madan J, Khatri D, Dua K. Amorphous systems for delivery of nutraceuticals: challenges opportunities. Crit Rev Food Sci Nutr 2020; 62:1204-1221. [PMID: 33103462 DOI: 10.1080/10408398.2020.1836607] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Amorphous solid products have recently gained a lot of attention as key solutions to improve the solubility and bioavailability of poorly soluble nutraceuticals. A pure amorphous drug is a high-energy form; physically/chemically unstable and so easily gets recrystallized into the less soluble crystalline form limiting solubility and bioavailability issues. Amorphous solid dispersion and co-amorphous are new formulation approach that stabilized unstable amorphous form through different mechanisms such as preventing mobility, high glass transition temperature and molecular interaction. Nutraceuticals have been received the utmost importance due to their health benefits. However, most of these compounds have been associated with poor oral bioavailability due to poor solubility, high lipophilicity, high melting point, poor permeability, degradability and rapid metabolism in the gastrointestinal tract (GIT) which limits its health benefits. This review provides us a systematic application of amorphous systems to the delivery of poorly soluble nutraceuticals, with the aim of overcoming their pharmacokinetic limitations and improved pharmacological potential. In particular, it describes the challenges associated with delivery of oral nutraceuticals, various methods involved in the preparation and characterization of amorphous systems and permeability enhancement of nutraceuticals are in detail.
Collapse
Affiliation(s)
- Devendrasingh Tomar
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Pankaj K Singh
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Sajidul Hoque
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Sheela Modani
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Anitha Sriram
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Rahul Kumar
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Jitender Madan
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Dharmendra Khatri
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Kamal Dua
- Discipline of Pharmacy, Graduate School of Health (GSH), The University of Technology Sydney, Ultimo, Australia
| |
Collapse
|
25
|
Liu J, Grohganz H, Rades T. Influence of polymer addition on the amorphization, dissolution and physical stability of co-amorphous systems. Int J Pharm 2020; 588:119768. [DOI: 10.1016/j.ijpharm.2020.119768] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2020] [Revised: 08/10/2020] [Accepted: 08/11/2020] [Indexed: 01/04/2023]
|
26
|
Stocker MW, Healy AM, Ferguson S. Spray Encapsulation as a Formulation Strategy for Drug-Based Room Temperature Ionic Liquids: Exploiting Drug–Polymer Immiscibility to Enable Processing for Solid Dosage Forms. Mol Pharm 2020; 17:3412-3424. [DOI: 10.1021/acs.molpharmaceut.0c00467] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Michael W. Stocker
- School of Chemical and Bioprocess Engineering, University College Dublin, Dublin 4, Ireland
| | - Anne Marie Healy
- SSPC, The SFI Research Centre for Pharmaceuticals, School of Pharmacy and Pharmaceutical Sciences, Panoz Institute, Trinity College Dublin, Dublin 2, Ireland
| | - Steven Ferguson
- School of Chemical and Bioprocess Engineering, University College Dublin, Dublin 4, Ireland
- SSPC, The SFI Research Centre for Pharmaceuticals, School of Chemical and Bioprocess Engineering, University College Dublin, Dublin 4, Ireland
- I-form, The SFI Research Centre for Advanced Manufacturing, School of Chemical and Bioprocess Engineering, University College Dublin, Dublin 4, Ireland
| |
Collapse
|
27
|
Degrees of order: A comparison of nanocrystal and amorphous solids for poorly soluble drugs. Int J Pharm 2020; 586:119492. [PMID: 32505579 DOI: 10.1016/j.ijpharm.2020.119492] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 05/29/2020] [Accepted: 05/30/2020] [Indexed: 02/07/2023]
Abstract
Poor aqueous solubility is currently a prevalent issue in the development of small molecule pharmaceuticals. Several methods are possible for improving the solubility, dissolution rate and bioavailability of Biopharmaceutics Classification System (BCS) class II and class IV drugs. Two solid state approaches, which rely on reductions in order, and can theoretically be applied to all molecules without any specific chemical prerequisites (compared with e.g. ionizable or co-former groups, or sufficient lipophilicity), are the use of the amorphous form and nanocrystals. Research involving these two approaches is relatively extensive and commercial products are now available based on these technologies. Nevertheless, their formulation remains more challenging than with conventional dosage forms. This article describes these two technologies from both theoretical and practical perspectives by briefly discussing the physicochemical backgrounds behind these approaches, as well as the resulting practical implications, both positive and negative. Case studies demonstrating the benefits and challenges of these two techniques are presented.
Collapse
|
28
|
Liu J, Rades T, Grohganz H. Determination of the Optimal Molar Ratio in Amino Acid-Based Coamorphous Systems. Mol Pharm 2020; 17:1335-1342. [PMID: 32119557 DOI: 10.1021/acs.molpharmaceut.0c00042] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Coamorphous drug formulations are a promising approach to improve solubility and bioavailability of poorly water-soluble drugs. On the basis of theoretical assumptions involving molecular interactions, the 1:1 molar ratio of drug and coformer is frequently used as "the optimal ratio" for a homogeneous coamorphous system (i.e., the coamorphous system with the highest physical stability and, if strong interaction is possible between two molecules, the highest glass transition temperature (Tg)). In order to more closely investigate this assumption, l-aspartic acid (ASP) and l-glutamic acid (GLU) were investigated as coformers for the basic drug carvedilol (CAR) at varying molar ratios. Salt formation between CAR with ASP or GLU was expected to occur at the molar 1:1 ratio based on their chemical structures. Interestingly, the largest deviation between the experimental Tg and the theoretical Tg based on the Gordon-Taylor equation was observed at a molar ratio of around 1:1.5 in CAR-ASP and CAR-GLU systems. In order to determine the exact value of the ratio with the highest Tg, a data fitting approach was established on thermometric data of various CAR-ASP and CAR-GLU systems. The highest Tg was found to be at CAR-ASP 1:1.46 and CAR-GLU 1:1.43 mathematically. Spectroscopic investigations and physical stability measurements further confirmed that the optimal molar ratio for obtaining a homogeneous system and the highest stability can be found at a molar ratio around 1:1.5. Overall, this study developed a novel approach to determine the optimal ratio between drug and coformers and revealed the influence of varying molar ratios on molecular interactions and physical stability in coamorphous systems.
Collapse
Affiliation(s)
- Jingwen Liu
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | - Thomas Rades
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
| |
Collapse
|
29
|
Jones ECL, Bimbo LM. Crystallisation Behaviour of Pharmaceutical Compounds Confined within Mesoporous Silicon. Pharmaceutics 2020; 12:E214. [PMID: 32121652 PMCID: PMC7150833 DOI: 10.3390/pharmaceutics12030214] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Revised: 02/17/2020] [Accepted: 02/21/2020] [Indexed: 12/20/2022] Open
Abstract
The poor aqueous solubility of new and existing drug compounds represents a significant challenge in pharmaceutical development, with numerous strategies currently being pursued to address this issue. Amorphous solids lack the repeating array of atoms in the structure and present greater free energy than their crystalline counterparts, which in turn enhances the solubility of the compound. The loading of drug compounds into porous materials has been described as a promising approach for the stabilisation of the amorphous state but is dependent on many factors, including pore size and surface chemistry of the substrate material. This review looks at the applications of mesoporous materials in the confinement of pharmaceutical compounds to increase their dissolution rate or modify their release and the influence of varying pore size to crystallise metastable polymorphs. We focus our attention on mesoporous silicon, due to the ability of its surface to be easily modified, enabling it to be stabilised and functionalised for the loading of various drug compounds. The use of neutron and synchrotron X-ray to examine compounds and the mesoporous materials in which they are confined is also discussed, moving away from the conventional analysis methods.
Collapse
Affiliation(s)
| | - Luis M. Bimbo
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK;
| |
Collapse
|
30
|
Hempel NJ, Knopp MM, Berthelsen R, Zeitler JA, Löbmann K. The influence of drug and polymer particle size on the in situ amorphization using microwave irradiation. Eur J Pharm Biopharm 2020; 149:77-84. [PMID: 32035238 DOI: 10.1016/j.ejpb.2020.01.019] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Revised: 01/16/2020] [Accepted: 01/31/2020] [Indexed: 10/25/2022]
Abstract
In this study, the impact of drug and polymer particle size on the in situ amorphization using microwave irradiation at a frequency of 2.45 GHz were investigated. Using ball milling and sieve fractioning, the crystalline drug celecoxib (CCX) and the polymer polyvinylpyrrolidone (PVP) were divided into two particle size fractions, i.e. small (<71 µm) and large (>71 µm) particles. Subsequently, compacts containing a drug load of 30% (w/w) crystalline CCX in PVP were prepared and subjected to microwave radiation for an accumulated duration of 600 sec in intervals of 60 sec as well as continuously for 600 sec. It was found that the compacts containing small CCX particles displayed faster rates of amorphization and a higher degree of amorphization during microwave irradiation as compared to the compacts containing large CCX particles. For compacts with small CCX particles, interval exposure to microwave radiation resulted in a maximum degree of amorphization of 24%, whilst a fully amorphous solid dispersion (100%) was achieved after 600 sec of continuous exposure to microwave radiation. By monitoring the temperature in the core of the compacts during exposure to microwave radiation using a fiber optic temperature probe, it was found that the total exposure time above the glass transition temperature (Tg) was shorter for the interval exposure method compared to continuous exposure to microwave radiation. Therefore, it is proposed that the in situ formation of an amorphous solid dispersion is governed by the dissolution of drug into the polymer, which most likely is accelerated above the Tg of the compacts. Hence, prolonging the exposure time above the Tg, and increasing the surface area of the drug by particle size reduction will increase the dissolution rate and thus, rate and degree of amorphization of CCX during exposure to microwave radiation.
Collapse
Affiliation(s)
| | | | - Ragna Berthelsen
- Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark
| | - J Axel Zeitler
- Department of Chemical Engineering, University of Cambridge, Cambridge CB2 3RA, UK
| | - Korbinian Löbmann
- Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark.
| |
Collapse
|
31
|
Ward RA, Anderton MJ, Bethel P, Breed J, Cook C, Davies EJ, Dobson A, Dong Z, Fairley G, Farrington P, Feron L, Flemington V, Gibbons FD, Graham MA, Greenwood R, Hanson L, Hopcroft P, Howells R, Hudson J, James M, Jones CD, Jones CR, Li Y, Lamont S, Lewis R, Lindsay N, McCabe J, McGuire T, Rawlins P, Roberts K, Sandin L, Simpson I, Swallow S, Tang J, Tomkinson G, Tonge M, Wang Z, Zhai B. Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC). J Med Chem 2019; 62:11004-11018. [DOI: 10.1021/acs.jmedchem.9b01295] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Richard A. Ward
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Mark J. Anderton
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Paul Bethel
- Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K
| | - Jason Breed
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Calum Cook
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Emma J. Davies
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Andrew Dobson
- Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K
| | - Zhiqiang Dong
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China
| | - Gary Fairley
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Paul Farrington
- Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Lyman Feron
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Vikki Flemington
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Francis D. Gibbons
- DMPK, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Mark A. Graham
- Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K
| | - Ryan Greenwood
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Lyndsey Hanson
- Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Philip Hopcroft
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Rachel Howells
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | | | | | | | | | - Yongchao Li
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China
| | - Scott Lamont
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Richard Lewis
- Medicinal Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden
| | - Nicola Lindsay
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - James McCabe
- Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K
| | - Thomas McGuire
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Philip Rawlins
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Karen Roberts
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | | | | | - Steve Swallow
- Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K
| | - Jia Tang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China
| | - Gary Tomkinson
- Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K
| | - Michael Tonge
- Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K
| | - Zhenhua Wang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China
| | - Baochang Zhai
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China
| |
Collapse
|
32
|
Machado Cruz R, Santos-Martinez MJ, Tajber L. Impact of polyethylene glycol polymers on the physicochemical properties and mucoadhesivity of itraconazole nanoparticles. Eur J Pharm Biopharm 2019; 144:57-67. [DOI: 10.1016/j.ejpb.2019.09.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 08/28/2019] [Accepted: 09/03/2019] [Indexed: 11/25/2022]
|
33
|
Russo MG, Baldoni HA, Dávila YA, Brusau EV, Ellena JA, Narda GE. Rational Design of a Famotidine-Ibuprofen Coamorphous System: An Experimental and Theoretical Study. J Phys Chem B 2018; 122:8772-8782. [PMID: 30160964 DOI: 10.1021/acs.jpcb.8b06105] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Famotidine (FMT) and ibuprofen (IBU) were used as model drugs to obtain coamorphous systems, where the guanidine moiety of the antacid and the carboxylic group of the nonsteroidal anti-inflammatory drug could potentially participate in H-bonds leading to a given structural motif. The systems were prepared in 3:7, 1:1, and 7:3 FMT and IBU molar ratios, respectively. The latter two became amorphous after 180 min of comilling. FMT-IBU (1:1) exhibited a higher physical stability in assays at 4, 25, and 40 °C up to 60 days. Fourier transform infrared spectroscopy accounted for important modifications in the vibrational behavior of those functional groups, allowing us to ascribe the skill of 1:1 FMT-IBU for remaining amorphous to equimolar interactions between both components. Density functional theory calculations followed by quantum theory of atoms in molecules analysis were then conducted to support the presence of the expected FMT-IBU heterodimer with consequent formation of a R228 structural motif. The electron density (ρ) and its Laplacian (∇2ρ) values suggested a high strength of the specific intermolecular interactions. Molecular dynamics simulations to build an amorphous assembly, followed by radial distribution function analysis on the modeled phase were further employed. The results demonstrate that it is a feasible rational design of a coamorphous system, satisfactorily stabilized by molecular-level interactions leading to the expected motif.
Collapse
Affiliation(s)
- Marcos G Russo
- Departamento de Química, Facultad de Química, Bioquímica y Farmacia , Universidad Nacional de San Luis , Chacabuco 917 , D5700HOJ San Luis , Argentina.,Instituto de Investigación en Tecnología Química (INTEQUI-UNSL), CONICET , Almirante Brown 1455 , D5700HGC San Luis , Argentina
| | - Hector A Baldoni
- Departamento de Química, Facultad de Química, Bioquímica y Farmacia , Universidad Nacional de San Luis , Chacabuco 917 , D5700HOJ San Luis , Argentina.,Instituto de Matemática Aplicada San Luis (IMASL-UNSL), CONICET , Italia 1556 , D5700HHW San Luis , Argentina
| | - Yamina A Dávila
- Departamento de Química, Facultad de Química, Bioquímica y Farmacia , Universidad Nacional de San Luis , Chacabuco 917 , D5700HOJ San Luis , Argentina.,Instituto de Investigación en Tecnología Química (INTEQUI-UNSL), CONICET , Almirante Brown 1455 , D5700HGC San Luis , Argentina
| | - Elena V Brusau
- Departamento de Química, Facultad de Química, Bioquímica y Farmacia , Universidad Nacional de San Luis , Chacabuco 917 , D5700HOJ San Luis , Argentina.,Instituto de Investigación en Tecnología Química (INTEQUI-UNSL), CONICET , Almirante Brown 1455 , D5700HGC San Luis , Argentina
| | - Javier A Ellena
- Instituto de Fisica de São Carlos , Universidad de São Paulo , CP 369, 13560-970 São Carlos , São Paulo , Brazil
| | - Griselda E Narda
- Departamento de Química, Facultad de Química, Bioquímica y Farmacia , Universidad Nacional de San Luis , Chacabuco 917 , D5700HOJ San Luis , Argentina.,Instituto de Investigación en Tecnología Química (INTEQUI-UNSL), CONICET , Almirante Brown 1455 , D5700HGC San Luis , Argentina
| |
Collapse
|
34
|
Wu W, Ueda H, Löbmann K, Rades T, Grohganz H. Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems. Eur J Pharm Biopharm 2018; 131:25-32. [PMID: 30040997 DOI: 10.1016/j.ejpb.2018.07.016] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 06/21/2018] [Accepted: 07/20/2018] [Indexed: 12/11/2022]
Abstract
Co-amorphous drug delivery systems are attracting increasing attention in the pharmaceutical field, due to their promising potential to improve the solubility and bioavailability of poorly water-soluble drugs. In this study, three organic acids, namely benzoic acid, malic acid and citric acid, were investigated as co-formers for the weakly basic drug carvedilol. It was hypothesised that the mono-, di- and triprotic nature of the organic acids could result in co-amorphous salt formation with carvedilol at the respective stoichiometric molar ratios, leading to different physicochemical properties of the co-amorphous samples. The carvedilol-organic acid samples were spray dried at molar ratios from 1:4 to 4:1 and amorphous products were obtained for all mixtures except for carvedilol-benzoic acid at a molar ratio of 1:4. A positive deviation of the glass transition temperature compared to the Gordon-Taylor equation was seen for all co-amorphous samples. Salt formation was confirmed by FTIR, but interestingly complete salt formation did not simply follow the molar ratio of the number of basic and acidic groups, most likely due to steric hindrance. As more than one molecule of carvedilol was found to be involved in most co-amorphous systems with the organic acids, this approach allows for a higher "drug loading" compared to other co-formers that usually form co-amorphous systems at a 1:1 M ratio. In addition, the large number of available organic acids offers various options for selecting co-formers.
Collapse
Affiliation(s)
- Wenqi Wu
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
| | - Hiroshi Ueda
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark; Research Laboratory for Development, Shionogi & Co., Ltd., Osaka, Japan
| | - Korbinian Löbmann
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
| | - Thomas Rades
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
| |
Collapse
|
35
|
A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation. Pharmaceutics 2018; 10:pharmaceutics10030085. [PMID: 29986403 PMCID: PMC6161109 DOI: 10.3390/pharmaceutics10030085] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 07/01/2018] [Accepted: 07/04/2018] [Indexed: 11/21/2022] Open
Abstract
Low physical stability is the limitation of the widespread use of amorphous drugs. The co-amorphous drug system is a new and emerging method for preparing a stable amorphous form. Co-amorphous is a single-phase amorphous multicomponent system consisting of two or more small molecules that are a combination of drugs or drugs and excipients. The co-amorphous system that uses benzoic acid (BA) as an excipient was studied to improve the physical stability, dissolution, and solubility of desloratadine (DES). In this study, the co-amorphous formation of DES and BA (DES–BA) was prepared by melt-quenching method and characterized by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction (PXRD), and polarized light microscopy (PLM). Dissolution, solubility, and physical stability profiles of DES–BA were determined. The DES crystals were converted into DES–BA co-amorphous form to reveal the molecular interactions between DES and BA. Solid-state analysis proved that the co-amorphous DES–BA system (1:1) is amorphous and homogeneous. The DSC experiment showed that the glass transition temperature (Tg) of tested DES–BA co-amorphous had a higher single Tg compared to the amorphous DES. FTIR revealed strong interactions, especially salt formation. The dissolution rate and solubility of co-amorphous DES–BA (1:1) obtained were larger than the DES in crystalline form. The PXRD technique was used to assess physical stability for three months at 40 °C with 75% RH. The DES–BA co-amorphous system demonstrated better physical stability than a single form of amorphous DES. Co-amorphous DES–BA has demonstrated the potential for improving solid-state stability, as the formation of DES–BA co-amorphous salt increased solubility and dissolution when compared to pure crystalline DES. This study also demonstrated the possibility for developing a DES–BA co-amorphous system toward oral formulations to improve DES solubility and bioavailability.
Collapse
|
36
|
Petry I, Löbmann K, Grohganz H, Rades T, Leopold CS. Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions. Int J Pharm 2018; 544:172-180. [PMID: 29669257 DOI: 10.1016/j.ijpharm.2018.04.026] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Revised: 04/12/2018] [Accepted: 04/13/2018] [Indexed: 10/25/2022]
Abstract
The use of co-amorphous systems for solubility enhancement of poorly water-soluble drugs has recently gained interest in the field of pharmaceutical technology. However, undesired co-amorphisation of a drug may lead to an alteration of the performance of the drug product, e.g. the previously observed co-amorphisation of indomethacin and arginine upon storage of tablets containing both components in an initially crystalline form at room temperature (RT) and 75% relative humidity (RH). Therefore, the aim of the present study was to further investigate this unintended co-amorphisation by storing plain crystalline γ-indomethacin and arginine as well as physical mixtures of both components at RT and three different RH levels (28, 58, and 75% RH). After storage for up to 101 days, their properties were analysed by X-ray powder diffraction, infrared spectroscopy, differential scanning calorimetry, thermogravimetric analysis, and HPLC. Results showed that the solid state of plain γ-indomethacin did not change during storage at all three storage conditions. In contrast, arginine was found to form a dihydrate upon storage at RT/58% RH and RT/75% RH. The physical mixtures, stored at RT/28% RH and RT/58% RH, remained crystalline and were chemically stable, while the formation of a co-amorphous salt between indomethacin and arginine as well as basic hydrolysis of indomethacin started already 1 day after exposure to RT/75% RH. Moreover, formation of a crystalline salt of indomethacin and arginine upon storage at RT/75% RH was observed. As neither of these instabilities occurred, if indomethacin was stored separately, the simultaneous effects of arginine and moisture on the solid state properties and chemical stability of indomethacin should be taken into account, if selecting arginine as excipient.
Collapse
Affiliation(s)
- Ina Petry
- Division of Pharmaceutical Technology, Department of Chemistry, University of Hamburg, Bundesstraße 45, 20146 Hamburg, Germany.
| | - Korbinian Löbmann
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Thomas Rades
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Claudia S Leopold
- Division of Pharmaceutical Technology, Department of Chemistry, University of Hamburg, Bundesstraße 45, 20146 Hamburg, Germany.
| |
Collapse
|
37
|
Corner PA, Harburn JJ, Steed JW, McCabe JF, Berry DJ. Stabilisation of an amorphous form of ROY through a predicted co-former interaction. Chem Commun (Camb) 2017; 52:6537-40. [PMID: 27109460 DOI: 10.1039/c6cc02949c] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The highly polymorphic compound ROY, notorious for the colour of its crystals, was the subject of an optimised high-throughput ultrasound-based co-crystal screen. This screen involved a computational pre-screen which highlighted an interaction between ROY and the potential co-former pyrogallol. We have shown that the presence of pyrogallol stabilises the amorphous form of ROY, highlighting the potential for future prediction of co-amorphous behaviours.
Collapse
Affiliation(s)
- Philip A Corner
- Durham University, Division of Pharmacy, Queen's Campus, Stockton on Tees, TS17 6BH, UK.
| | - J Jonathan Harburn
- Durham University, Division of Pharmacy, Queen's Campus, Stockton on Tees, TS17 6BH, UK.
| | - Jonathan W Steed
- Department of Chemistry, Durham University, University Science Laboratories, South Road, Durham, DH1 3LE, UK
| | - James F McCabe
- Pharmaceutical Development, AstraZeneca Macclesfield, SK10 2SN, UK
| | - David J Berry
- Durham University, Division of Pharmacy, Queen's Campus, Stockton on Tees, TS17 6BH, UK.
| |
Collapse
|
38
|
Doreth M, Löbmann K, Priemel P, Grohganz H, Taylor R, Holm R, Lopez de Diego H, Rades T. Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin. Eur J Pharm Biopharm 2017; 122:62-69. [PMID: 28986296 DOI: 10.1016/j.ejpb.2017.10.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 10/02/2017] [Accepted: 10/02/2017] [Indexed: 11/25/2022]
Abstract
In situ amorphization is an approach that enables a phase transition of a crystalline drug to its amorphous form immediately prior to administration. In this study, three different polyvinylpyrrolidones (PVP K12, K17 and K25) were selected to investigate the influence of the molecular weight of the polymer on the degree of amorphization of the model drug indomethacin (IND) upon microwaving. Powder mixtures of crystalline IND and the respective PVP were compacted at 1:2 (w/w) IND:PVP ratios, stored at 54% RH and subsequently microwaved with a total energy input of 90 or 180kJ. After storage, all compacts had a similar moisture content (∼10% (w/w)). Upon microwaving with an energy input of 180kJ, 58±4% of IND in IND:PVP K12 compacts was amorphized, whereas 31±8% of IND was amorphized by an energy input of 90kJ. The drug stayed fully crystalline in all IND:PVP K17 and IND:PVP K25 compacts. After plasticization by moisture, PVP K12 reached a Tg below ambient temperature (16±2°C) indicating that the Tg of the plasticized polymer is a key factor for the success of in situ amorphization. DSC analysis showed that the amorphized drug was part of a ternary glass solution consisting of IND, PVP K12 and water. In dissolution tests, IND:PVP K12 compacts showed a delayed initial drug release due to a lack of compact disintegration, but reached a higher total drug release eventually. In summary, this study showed that the microwave assisted in situ amorphization was highly dependent on the Tg of the plasticized polymer.
Collapse
Affiliation(s)
- Maria Doreth
- Department of Pharmacy, Faculty of Health, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Korbinian Löbmann
- Department of Pharmacy, Faculty of Health, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Petra Priemel
- Department of Pharmacy, Faculty of Health, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Holger Grohganz
- Department of Pharmacy, Faculty of Health, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
| | - Robert Taylor
- Sirius Analytical Instruments Ltd., Station Rd, Forest Row RH18 5DW, United Kingdom.
| | - René Holm
- Department of Pharmacy, Faculty of Health, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark; Drug Product Development, Janssen Research and Development, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium.
| | - Heidi Lopez de Diego
- Analytical Development & Compliance, H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark.
| | - Thomas Rades
- Department of Pharmacy, Faculty of Health, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark; Department of Pharmacy, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.
| |
Collapse
|
39
|
Petry I, Löbmann K, Grohganz H, Rades T, Leopold CS. Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect. Eur J Pharm Biopharm 2017; 119:150-160. [PMID: 28602869 DOI: 10.1016/j.ejpb.2017.06.007] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2017] [Revised: 06/01/2017] [Accepted: 06/07/2017] [Indexed: 11/19/2022]
Abstract
A promising approach to improve the solubility of poorly water-soluble drugs and to overcome the stability issues related to the plain amorphous form of the drugs, is the formulation of drugs as co-amorphous systems. Although polymer coatings have been proven very useful with regard to tablet stability and modifying drug release, there is little known on coating co-amorphous formulations. Hence, the aim of the present study was to investigate whether polymer coating of co-amorphous formulations is possible without inducing recrystallization. Tablets containing either a physical mixture of crystalline indomethacin and arginine or co-amorphous indomethacin-arginine were coated with a water soluble polyvinyl alcohol-polyethylene glycol graft copolymer (Kollicoat® Protect) and stored at 23°C/0% RH and 23°C/75% RH. The solid state properties of the coated tablets were analyzed by XRPD and FTIR and the drug release behavior was tested for up to 4h in phosphate buffer pH 4.5. The results showed that the co-amorphous formulation did not recrystallize during the coating process or during storage at both storage conditions for up to three months, which confirmed the high physical stability of this co-amorphous system. Furthermore, the applied coating could partially inhibit recrystallization of indomethacin during drug release testing, as coated tablets reached a higher level of supersaturation compared to the respective uncoated formulations and showed a lower decrease of the dissolved indomethacin concentration upon precipitation. Thus, the applied coating enhanced the AUC of the dissolution curve of the co-amorphous tablets by about 30%. In conclusion, coatings might improve the bioavailability of co-amorphous formulations.
Collapse
Affiliation(s)
- Ina Petry
- Div. of Pharmaceutical Technology, Dept. of Chemistry, University of Hamburg, Bundesstraße 45, 20146 Hamburg, Germany.
| | - Korbinian Löbmann
- Dept. of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100, Denmark.
| | - Holger Grohganz
- Dept. of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100, Denmark.
| | - Thomas Rades
- Dept. of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100, Denmark.
| | - Claudia S Leopold
- Div. of Pharmaceutical Technology, Dept. of Chemistry, University of Hamburg, Bundesstraße 45, 20146 Hamburg, Germany.
| |
Collapse
|
40
|
Lim RTY, Ong CK, Cheng S, Ng WK. Amorphization of crystalline active pharmaceutical ingredients via formulation technologies. POWDER TECHNOL 2017. [DOI: 10.1016/j.powtec.2017.01.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
41
|
Jensen LG, Skautrup FB, Müllertz A, Abrahamsson B, Rades T, Priemel PA. Amorphous is not always better-A dissolution study on solid state forms of carbamazepine. Int J Pharm 2017; 522:74-79. [PMID: 28263832 DOI: 10.1016/j.ijpharm.2017.02.062] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2017] [Revised: 02/21/2017] [Accepted: 02/22/2017] [Indexed: 11/17/2022]
Abstract
Poor aqueous solubility is a major concern for many new drugs. One possibility to overcome this issue is to formulate the drug as a high energy form, i.e. a metastable polymorph, an amorphous neat drug or a glass solution with polymers. In this study the dissolution properties of different solid state forms of carbamazepine, crystalline or amorphous drug, with or without either polyvinylpyrrolidone (PVP) or hydroxypropylmethylcellulose (HPMC) and glass solutions of the drug with both polymers (2:1, 4:1 and 10:1 (w/w) drug-to-polymer ratio) were tested with respect to their dissolution behaviour in a biorelevant gastric medium (for 30min) and subsequently in intestinal conditions (for 2h). Carbamazepine form III in the absence of polymer dissolved to a drug concentration of 540μg/ml, but the concentration decreased after around 70min due to precipitation of the dihydrate form, and reached 436μg/ml after 2.5h dissolution testing. The presence of PVP led to a similar dissolution profile with a slightly earlier onset of decrease in drug concentration, while in the presence of HPMC no decline in dissolved drug concentration was observed. Surprisingly, amorphous carbamazepine did not result in any supersaturation and the drug concentration was lower than that measured for crystalline carbamazepine. The addition of polymers further decreased the concentration of dissolved drug (290-310μg/ml, depending on polymer type and concentration). Amorphous drug converted quickly into the dihydrate form and thus no supersaturation was achieved. Glass solutions of carbamazepine with PVP reached drug concentrations between 348 and 408μg/ml after 2.5h, i.e. lower than for the crystalline drug, whilst glass solutions with HPMC reached concentrations similar to the crystalline drug.
Collapse
Affiliation(s)
- Linda G Jensen
- University of Copenhagen, School of Pharmaceutical Sciences, Denmark
| | | | - Anette Müllertz
- University of Copenhagen, School of Pharmaceutical Sciences, Denmark; Bioneer:Farma, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | | | - Thomas Rades
- University of Copenhagen, School of Pharmaceutical Sciences, Denmark.
| | - Petra A Priemel
- University of Copenhagen, School of Pharmaceutical Sciences, Denmark
| |
Collapse
|
42
|
Co amorphous systems: A product development perspective. Int J Pharm 2016; 515:403-415. [DOI: 10.1016/j.ijpharm.2016.10.043] [Citation(s) in RCA: 96] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2016] [Revised: 10/18/2016] [Accepted: 10/19/2016] [Indexed: 11/21/2022]
|
43
|
Doreth M, Löbmann K, Grohganz H, Holm R, Lopez de Diego H, Rades T, Priemel PA. Glass solution formation in water - In situ amorphization of naproxen and ibuprofen with Eudragit® E PO. J Drug Deliv Sci Technol 2016. [DOI: 10.1016/j.jddst.2016.02.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Unintended and in situ amorphisation of pharmaceuticals. Adv Drug Deliv Rev 2016; 100:126-32. [PMID: 26724250 DOI: 10.1016/j.addr.2015.12.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Revised: 11/28/2015] [Accepted: 12/16/2015] [Indexed: 01/11/2023]
Abstract
Amorphisation of poorly water-soluble drugs is one approach that can be applied to improve their solubility and thus their bioavailability. Amorphisation is a process that usually requires deliberate external energy input. However, amorphisation can happen both unintentionally, as in process-induced amorphisation during manufacturing, or in situ during dissolution, vaporisation, or lipolysis. The systems in which unintended and in situ amorphisation has been observed normally contain a drug and a carrier. Common carriers include polymers and mesoporous silica particles. However, the precise mechanisms by which in situ amorphisation occurs are often not fully understood. In situ amorphisation can be exploited and performed before administration of the drug or possibly even within the gastrointestinal tract, as can be inferred from in situ amorphisation observed during in vitro lipolysis. The use of in situ amorphisation can thus confer the advantages of the amorphous form, such as higher apparent solubility and faster dissolution rate, without the disadvantage of its physical instability.
Collapse
|
45
|
Preparation of polymeric fenofibrate formulations with accelerated drug release: Solvent evaporation versus co-grinding. J Drug Deliv Sci Technol 2015. [DOI: 10.1016/j.jddst.2015.07.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
46
|
Jensen KT, Löbmann K, Rades T, Grohganz H. Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline. Pharmaceutics 2014; 6:416-35. [PMID: 25025400 PMCID: PMC4190527 DOI: 10.3390/pharmaceutics6030416] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Revised: 06/23/2014] [Accepted: 07/01/2014] [Indexed: 12/01/2022] Open
Abstract
Co-amorphous drug amino acid mixtures were previously shown to be a promising approach to create physically stable amorphous systems with the improved dissolution properties of poorly water-soluble drugs. The aim of this work was to expand the co-amorphous drug amino acid mixture approach by combining the model drug, naproxen (NAP), with an amino acid to physically stabilize the co-amorphous system (tryptophan, TRP, or arginine, ARG) and a second highly soluble amino acid (proline, PRO) for an additional improvement of the dissolution rate. Co-amorphous drug-amino acid blends were prepared by ball milling and investigated for solid state characteristics, stability and the dissolution rate enhancement of NAP. All co-amorphous mixtures were stable at room temperature and 40 °C for a minimum of 84 days. PRO acted as a stabilizer for the co-amorphous system, including NAP–TRP, through enhancing the molecular interactions in the form of hydrogen bonds between all three components in the mixture. A salt formation between the acidic drug, NAP, and the basic amino acid, ARG, was found in co-amorphous NAP–ARG. In comparison to crystalline NAP, binary NAP–TRP and NAP–ARG, it could be shown that the highly soluble amino acid, PRO, improved the dissolution rate of NAP from the ternary co-amorphous systems in combination with either TRP or ARG. In conclusion, both the solubility of the amino acid and potential interactions between the molecules are critical parameters to consider in the development of co-amorphous formulations.
Collapse
Affiliation(s)
| | - Korbinian Löbmann
- Department of Pharmacy, University of Copenhagen, Copenhagen 2100, Denmark.
| | - Thomas Rades
- Department of Pharmacy, University of Copenhagen, Copenhagen 2100, Denmark.
| | - Holger Grohganz
- Department of Pharmacy, University of Copenhagen, Copenhagen 2100, Denmark.
| |
Collapse
|
47
|
Grohganz H, Priemel PA, Löbmann K, Nielsen LH, Laitinen R, Mullertz A, Van den Mooter G, Rades T. Refining stability and dissolution rate of amorphous drug formulations. Expert Opin Drug Deliv 2014; 11:977-89. [DOI: 10.1517/17425247.2014.911728] [Citation(s) in RCA: 98] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
48
|
Priemel PA, Laitinen R, Grohganz H, Rades T, Strachan CJ. In situ amorphisation of indomethacin with Eudragit® E during dissolution. Eur J Pharm Biopharm 2013; 85:1259-65. [PMID: 24056054 DOI: 10.1016/j.ejpb.2013.09.010] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Revised: 08/12/2013] [Accepted: 09/11/2013] [Indexed: 01/25/2023]
Abstract
In this study, the possibility of utilising in situ crystalline-to-amorphous transformation for the delivery of poorly water soluble drugs was investigated. Compacts of physical mixtures of γ-indomethacin (IMC) and Eudragit® E in 3:1, 1:1 and 1:3 (w/w) ratios were subjected to dissolution testing at pH 6.8 at which IMC but not the polymer is soluble. Compacts changed their colour from white to yellow indicating amorphisation of IMC. X-ray powder diffractometry (XRPD) confirmed the amorphisation and only one glass transition temperature was observed (58.1 °C, 54.4 °C, and 50.1 °C for the 3:1, 1:1 and 1:3 (w/w) drug-to-polymer ratios, respectively). Furthermore, principal component analysis of infrared spectra resulted in clustering of in situ transformed samples together with quench cooled glass solutions for each respective ratio. Subsequent dissolution testing of in situ transformed samples at pH 4.1, at which the polymer is soluble but not IMC, led to a higher dissolution rate than for quench cooled glass solution at 3:1 and 1:1 ratios, but not for the 1:3 ratio. This study showed that crystalline drug can be transformed into amorphous material in situ in the presence of a polymer, leading to the possibility of administering drugs in the amorphous state without physical instability problems during storage.
Collapse
Affiliation(s)
- Petra A Priemel
- School of Pharmacy, University of Otago, New Zealand; School of Pharmacy, University of Eastern Finland, Finland; Department of Pharmacy, University of Copenhagen, Denmark
| | | | | | | | | |
Collapse
|